Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer

Osugi, Jun; Yamaura, Takumi; Muto, Satoshi; Okabe, Naoyuki; Matsumura, Yuki; Hoshino, Mika; Higuchi, Mitunori; Suzuki, Hiroyuki; Gotoh, Mitsukazu

doi:10.1016/j.lungcan.2015.03.004

Cited by 54 publications

(46 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our results revealed a favorable clinical outcome in patients with GLUT1-positive advanced-stage cHL, previous studies revealed correlations between high GLUT1 expression and poor survival in other solid malignancies [5-8]. In the present study, all patients received the ABVD regimen.…”

Section: Discussioncontrasting

confidence: 50%

See 1 more Smart Citation

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression

Koh

Han

Park

et al. 2017

J Pathol Transl Med

View full text Add to dashboard Cite

BackgroundGlucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or refractory classical Hodgkin’s lymphoma (cHL). The purpose of this study was to measure the expression of GLUT1 and assess its prognostic significance and potential relationships with PD-L1, programmed death ligand 2 (PD-L2), and programmed death-1 (PD-1) expressions in cHL.MethodsDiagnostic tissues from 125 patients with cHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine were evaluated retrospectively via immunohistochemical analysis of GLUT1, PD-L1, PD-L2, and PD-1 expression.ResultsThe median follow-up time was 4.83 years (range, 0.08 to 17.33 years). GLUT1, PD-L1, PD-L2, and PD-1 were expressed in 44.8%, 63.2%, 9.6%, and 13.6% of the specimens, respectively. Positive correlations were found between GLUT1 and PD-L1 expression (p = .004) and between GLUT1 and PD-L2 expression (p = .031). GLUT1 expression in Hodgkin/Reed-Sternberg (HRS) cells was not associated with overall survival or event-free survival (EFS) in the entire cohort (p = .299 and p = .143, respectively). A subgroup analysis according to the Ann Arbor stage illustrated that GLUT1 expression in HRS cells was associated with better EFS in advanced-stage disease (p = .029). A multivariate analysis identified GLUT1 as a marginally significant prognostic factor for EFS (p = .068).ConclusionsThis study suggests that GLUT1 expression is associated with better clinical outcomes in advanced-stage cHL and is significantly associated with PD-L1 and PD-L2 expressions.

show abstract

Section: Discussioncontrasting

confidence: 50%

“…GLUT1 overexpression has been correlated with a poor prognosis in several cancers including the lung [5], breast [6], colon [7], and stomach cancers [8]. Although GLUT1 expression was evaluated in cHL [9,10], it was not associated with clinical outcomes in a previous study [9].…”

mentioning

confidence: 99%

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression

Koh

Han

Park

et al. 2017

J Pathol Transl Med

View full text Add to dashboard Cite

show abstract

“…The main characteristics of included researches were presented in Table 1. Five researches appraised colorectal cancer [20–23, 33], five evaluated orals squamous cell carcinoma [24–28], three evaluated cervical cancer [35, 36, 38], two studies evaluated lung cancer [14, 15], two evaluated breast cancer [16, 17], two studies evaluated pancreatic cancer [19, 34] and one each evaluated esophageal cancer [18], hepatocellular carcinoma[10], gallbladder carcinoma [19], bladder cancer [29], ovarian cancer [30], head and neck squamous cell carcinoma [31], renal cancer [37], and salivary gland tumor [32]. All these 26 studies evaluated GLUT1.…”

Section: Resultsmentioning

confidence: 99%

“…A myriad of studies showed that elevated expression level of GLUT1 in malignant tumors was correlated with poor clinical outcomes in patients with diverse types of solid tumors such as lung cancer [14, 15], breast cancer [16, 17], esophageal cancer [18], hepatocellular carcinoma [10], gallbladder carcinoma [19], colorectal cancer [20–23], oral squamous cell carcinoma [24–28], bladder cancer [29], ovarian cancer [30], head and neck squamous cell carcinoma [31], and salivary gland tumor [32]. However, some other researches showed overexpression of GLUT1 was related to favorable clinical outcome [33].…”

Section: Introductionmentioning

confidence: 99%

Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis

Chen

et al. 2017

Oncotarget

156

View full text Add to dashboard Cite

Glucose transporter 1 (GLUT1), the uniporter protein encoded by the SLC2A1 gene, is a key rate-limiting factor in the transport of glucose in cancer cells, and frequently expressed in a significant proportion of human cancers. Numerous studies have reported paradoxical evidence of the relationship between GLUT1 expression and prognosis in solid human tumors. To address this discrepancy, we conducted a thorough search of Pubmed and Web of Science for studies evaluating the expression of GLUT1 and overall survival (OS) and disease-free survival (DFS) in patients with solid cancer from 1993 to April 2016. Data from published researches were extracted and computed into odds ratio (OR). A total of 26 studies including 2948 patients met our search criteria and were evaluated. Overexpression of GLUT1 was found to significantly correlate with poor 3-year OS (OR: 2.86; 95% CI, 1.90–4.32, P < 0.00001) and 5-year OS (OR: 2.52; 95% CI, 1.75–3.61, P < 0.00001) of solid tumors. Similar results were observed when analysis of DFS was performed. Subgroup analysis revealed that elevated GLUT1 expression was associated with worse prognosis of oral squamous cell carcinoma and breast cancer. Taken together, overexpression of GLUT1 is correlated with poor survival in most solid tumors, suggesting that the expression status of GLUT1 is a vital prognostic indicator and promising therapeutic target in solid tumors.

show abstract

“…GLUT-1 was found to be correlated with biological behaviors of different tumors [24, 25]. In addition, GLUT-1 overexpression was also found to be associated with cancer progression and poor survival outcomes in different types of cancer, including bone and soft-tissue sarcomas [26], colorectal cancer [27], breast cancer [28], and lung cancer [29]. The findings of the present meta-analysis were in line with the results of previous studies on other types of cancer.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients

et al. 2017

View full text Add to dashboard Cite

ObjectivePrevious studies have suggested a correlation between glucose transporter-1 (GLUT-1) expression and survival outcomes in pancreatic cancer, although the results were inconsistent. We subsequently carried out a meta-analysis, with the aim of comprehensively reevaluating the associations between GLUT-1 expression and overall survival (OS) and other clinical features of pancreatic cancer.ResultsEight studies, with a total of 538 cases, were included in the final meta-analysis. The HR and 95% CI for OS were 1.79 and 1.19-2.7, respectively (p=0.005). GLUT-1 overexpression was associated with tumor size (>2 cm vs. ≤2 cm; OR=2.16, 95% CI=1.2-3.9, p=0.01) and lymph node metastasis (yes vs. no; OR=3.29, 95% CI=1.38-7.84, p=0.007). However, there was no significant association between GLUT-1 expression and histological grade, age, sex, TNM stage, or vascular invasion status. There was no evidence of significant publication bias in this meta-analysis.Materials and MethodsRelevant databases were searched using predefined searching items until September 2016. The pooled hazard ratios (HR) with 95% confidence interval (CI) for OS and the pooled odds ratio (OR) with 95% CI for clinical factors were calculated.ConclusionsHigh GLUT-1 expression predicted shorter OS in patients with pancreatic cancer. Moreover, GLUT-1 expression was associated with a tumor size of >2 cm and presence of lymph node metastasis.

show abstract

Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer

Cited by 54 publications

References 33 publications

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression

Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis

Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients

Contact Info

Product

Resources

About